This growth is fueled by the rising prevalence of lumbar disc herniation, an aging population, and the increasing demand for advanced pain management therapies. Since sciatica impacts nearly 40% of people at some point in their lives, healthcare systems worldwide are focusing on better diagnostic and treatment solutions.

Key drivers include the adoption of minimally invasive surgeries, wider acceptance of alternative therapies like physiotherapy and acupuncture, and AI-driven diagnostic tools that improve early detection. However, challenges such as high surgical costs, risks of complications, and limited reimbursement in some regions remain barriers to adoption. Despite this, drug-based treatments such as NSAIDs and antidepressants continue to dominate the market while newer therapies steadily gain traction.

Regionally, North America leads the sciatica market due to advanced healthcare infrastructure and favorable reimbursement policies, while Asia-Pacific is the fastest-growing region thanks to expanding healthcare access and aging populations in China and India. Major players like Novartis, AstraZeneca, Teva, and Endo Pharmaceuticals are investing in innovative treatment options, signaling strong future opportunities. The market is set to evolve with integrated approaches that blend pharmacological treatments, digital therapeutics, and holistic care.